Cargando…

Nitric oxide versus epoprostenol for refractory hypoxemia in Covid-19

OBJECTIVE: To compare the efficacy and outcomes with inhaled nitric oxide (iNO) and inhaled epoprostenol (iEPO) in patients with refractory hypoxemia due to COVID-19. DESIGN: Retrospective Cohort Study. SETTING: Single health system multicenter academic teaching hospitals. PATIENTS OR SUBJECTS: Age...

Descripción completa

Detalles Bibliográficos
Autores principales:	Poonam, Pai B. H., Koscik, Rebecca, Nguyen, Trong, Rikhi, Shefali, Lin, Hung-Mo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9236233/ https://www.ncbi.nlm.nih.gov/pubmed/35759496 http://dx.doi.org/10.1371/journal.pone.0270646

Ejemplares similares

Evaluation of the Efficacy and Safety of Inhaled Epoprostenol and Inhaled Nitric Oxide for Refractory Hypoxemia in Patients With Coronavirus Disease 2019
por: DeGrado, Jeremy R., et al.
Publicado: (2020)

Effects of Inhaled Epoprostenol and Prone Positioning in Intubated Coronavirus Disease 2019 Patients With Refractory Hypoxemia
por: Li, Jie, et al.
Publicado: (2020)

Comparison of acute hemodynamic effects of inhaled nitric oxide and inhaled epoprostenol in patients with pulmonary hypertension
por: Preston, Ioana R., et al.
Publicado: (2013)

Management of refractory hypoxemia
por: Mehta, Chitra, et al.
Publicado: (2016)

Epoprostenol: Flushing or Erythroderma?
por: Martínez-Martínez, María Luisa, et al.
Publicado: (2013)

Epoprostenol Delivered via High Flow Nasal Cannula for ICU Subjects with Severe Hypoxemia Comorbid with Pulmonary Hypertension or Right Heart Dysfunction
por: Li, Jie, et al.
Publicado: (2019)

Epoprostenol Exposure During Pregnancy
por: Naoum, Emily E., et al.
Publicado: (2023)

Refractory Cardiogenic Shock from Right Ventricular Infarction Successfully Managed with Inhaled Epoprostenol
por: Held, Natalie, et al.
Publicado: (2017)

Inhaled pulmonary vasodilators in refractory hypoxemia
por: Wright, Brian J.
Publicado: (2015)

Epoprostenol: Exacerbation of thrombocytopenia : case report
Publicado: (2021)

Stress Cardiomyopathy Precipitated by Withdrawal of Epoprostenol
por: Gionfriddo, William J., et al.
Publicado: (2020)

Inhaled nitric oxide therapy for severe hypoxemia in hyperinflated mechanically ventilated bronchiolitis patient
por: DonaireGarcia, Alvaro, et al.
Publicado: (2022)

Responsiveness of Inhaled Epoprostenol in Respiratory Failure due to COVID-19
por: Sonti, Rajiv, et al.
Publicado: (2020)

Epoprostenol sodium for treatment of pulmonary arterial hypertension
por: Saito, Yukihiro, et al.
Publicado: (2015)

Use of Epoprostenol in the Treatment of Pulmonary Arterial Hypertension
por: Mohammadi, Asma, et al.
Publicado: (2021)

Alteplase/epoprostenol: Lack of efficacy: case report
Publicado: (2022)

Epoprostenol‐associated ascites in pulmonary arterial hypertension
por: Schoenberg, Noah C., et al.
Publicado: (2022)

HIGH-FLOW NASAL CANULA AND INHALED EPOPROSTENOL RESPONSE IN COVID-19
por: KHURANA, NEHARIKA, et al.
Publicado: (2022)

Rescue strategies for refractory hypoxemia: a critical appraisal
por: Villar, Jesús, et al.
Publicado: (2009)

A Case Report of Cyanosis With Refractory Hypoxemia: Is It Methemoglobinemia?
por: Kamath, Sangita D, et al.
Publicado: (2022)

In-vitro and in-vivo comparisons of high versus low concentrations of inhaled epoprostenol to adult intubated patients
por: Li, Jie, et al.
Publicado: (2021)

Inhaled Nitric Oxide as an Adjunct to Thrombolytic Therapy in a Patient with Submassive Pulmonary Embolism and Severe Hypoxemia
por: Toolsie, Omesh, et al.
Publicado: (2019)

Extracorporeal membrane oxygenation circuits in parallel for refractory hypoxemia in patients with COVID-19
por: Patel, Yatrik J., et al.
Publicado: (2022)

Steroids are part of rescue therapy in ARDS patients with refractory hypoxemia: no
por: Thompson, B. Taylor, et al.
Publicado: (2016)

Refractory hypoxemia caused by hepatopulmonary syndrome: a case report
por: Govindan, Morgen L, et al.
Publicado: (2014)

Effects of inhaled nitric oxide for postoperative hypoxemia in acute type A aortic dissection: a retrospective observational study
por: Zhang, Hang, et al.
Publicado: (2020)

Nitric Oxide Inhalation Therapy Attenuates Postoperative Hypoxemia in Obese Patients with Acute Type A Aortic Dissection
por: Zheng, Ping, et al.
Publicado: (2022)

Intravenous Epoprostenol for Management of Pulmonary Arterial Hypertension during Pregnancy
por: Timofeev, Julia, et al.
Publicado: (2013)

Microbial challenge test of a novel epoprostenol sodium formulation
por: Bandilla, Dirk, et al.
Publicado: (2017)

Successful use of inhaled epoprostenol as rescue therapy for pediatric ARDS
por: Urich, Alissa, et al.
Publicado: (2020)

Goiter in a Patient with Pulmonary Arterial Hypertension Treated with Epoprostenol
por: Abughazaleh, Shaadi, et al.
Publicado: (2020)

Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience
por: Sitbon, Olivier, et al.
Publicado: (2017)

PSAT054 Isolated ACTH Deficiency in a Patient on Epoprostenol
por: Riordan, Marianne, et al.
Publicado: (2022)

REFRACTORY HYPOXEMIA: A CASE OF DAPSONE-INDUCED METHEMOGLOBINEMIA IN A PATIENT WITH COVID-19
por: ALONSO, MILEYDIS, et al.
Publicado: (2022)

High-Frequency Oscillatory Ventilation for Refractory Hypoxemia in Severe COVID-19 Pneumonia: A Small Case Series
por: Keith, Philip, et al.
Publicado: (2022)

COMPARISON OF HIGHER VERSUS LOWER DOSE STEROID ADMINISTRATION IN PATIENTS WITH COVID-19 AND ACUTE HYPOXEMIC RESPIRATORY FAILURE ON INHALED EPOPROSTENOL
por: RIEGO, MARIA ATHENA, et al.
Publicado: (2022)

Retracted: Nitric Oxide Inhalation Therapy Attenuates Postoperative Hypoxemia in Obese Patients with Acute Type A Aortic Dissection
por: Methods in Medicine, Computational and Mathematical
Publicado: (2023)

Hospitalization and Survival in Patients Using Epoprostenol for Injection in the PROSPECT Observational Study
por: Frantz, Robert P., et al.
Publicado: (2015)

Withdrawal of long-term epoprostenol therapy in pulmonary arterial hypertension (PAH)
por: Calcaianu, George, et al.
Publicado: (2017)

Long-term outcomes of epoprostenol therapy in sarcoid associated pulmonary hypertension
por: Abston, Eric, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_okk18unv8ckqf6ppl9uj5aeidv